By

Laura Leszczynski
Sticky Post
In a significant step forward for veterans' healthcare, SoftWave Tissue Regeneration Technologies (SoftWave TRT) has been awarded a Federal Supply Schedule Contract by the Department of Veterans Affairs. Effective from July 15, 2023, to July 14, 2028, the contract—numbered 36F79723D01671—falls under Schedule 65 II A, dedicated to Medical Equipment and Supplies as part of Federal Supply Schedule...
Read More
At the May meeting, the Current Procedural Terminology (CPT) Editorial Panel approved the reimbursement code X170T that was developed and submitted by SoftWave for Low Intensity Extracorporeal Shock Wave Therapy (Li-ESWT). Kennesaw, GA, May, 4– In March 2022, Chris Holt joined SoftWave TRT as a strategic advisor and co-CEO, bolstering the company's growth and clinical...
Read More
SoftWave TRT has been selected to exhibit at the Vizient Innovative Technology Exchange.
Read More
SoftWave Tissue Regeneration Technologies has received an Innovative Technology contract from Vizient, Inc.
Read More
Patients are stuck and searching for non-surgical alternatives. SoftWave is a cost-effective alternative to joint replacement surgery.
Read More
SoftWave officially has been granted 4 new patents as of July 19, 200. They include e U.S. Patient No. 11,389,373 B2 for Acoustic shock wave therapeutic methods to prevent or treat opioid addiction, U.S. Patient No. 11,389,370 B2 for Treatments for blood sugar levels and muscle tissue optimization, U.S. Patient No. 11,389,371 B2 and U.S....
Read More
Hypertrophic scars cause aesthetic concerns and negatively affect the quality of life. A gold standard treatment for hypertrophic scars has not been established due to various responses of modalities. Extracorporeal shock wave therapy (ESWT) is a noninvasive and affects scar remodeling by fibroblast regulation. This study investigated the effectiveness of ESWT for hypertrophic scars. Click...
Read More